Europe Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143385
- Pages: 225
-
Format:
Short Description
Europe Foot And Ankle Allografts Market, By Product Type (Allograft Wedges, Allograft Tendons, Allograft Acellular Dermal Matrix, Cartilage Allograft Matrix, Skin Allografts, Amniotic Membranes), Surgery Type (Orthopedic Reconstruction, Cartilage Restoration, Soft Tissue Tendon & Ligament Repair, Wound Care) Procedure (Midfoot Procedures, Hindfoot Procedures), End User (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Other End Users) Industry Trends & Forecast to 2029.
Market Definition:
Allografts are most commonly used in reconstructive surgeries around the foot and ankle. Compared to autograft tissue, allografts provide advantages such as less operative time, unlimited tissue sources, and lack of potential donors-site morbidity.
The demand for foot and ankle allografts has been increased in both developed well as in developing countries and the reason behind this is the increasing chronic disease population. The foot and ankle allografts market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets and strategic initiatives by market players
Market Segmentation:
Foot and ankle allografts market is categorized into four notable segment which is product type, surgery type, procedure and end user.
On the basis of product type, Europe foot and ankle allograft market is segmented into allograft wedges, allograft tendons, allograft, acellular dermal matrix, cartilage allograft matrix, skin allografts, and amniotic membranes. In 2022, allograft wedges segment in global foot and ankle allograft market is expected to growing in the market with the increasing demand for allografts in orthopedics.
On the basis of surgery type, Europe foot and ankle allograft market is segmented into orthopedic reconstruction, cartilage restoration, soft tissue tendon & ligament repair and wound care. In 2022, orthopedic reconstruction segment in global foot and ankle allograft market is expected to growing in the market with the increasing rising R&D activities by major market players.
On the basis of procedure, Europe foot and ankle allograft market is segmented into midfoot procedures and hind-foot procedures. In 2022, midfoot procedures segment in global foot and ankle allograft market is expected to grow with the increasing use of foot and ankle allograft and increasing muscle-Skelton disorders.
On the basis of end user, Europe foot and ankle allograft market is segmented into hospitals, orthopedic clinics, ambulatory surgical centers, academic and research institutes and other end users. In 2022, hospital segment in global foot and ankle allograft market is expected to growing in the market with the increasing patient population and orthopedic diseases in hospitals
Market Players
The key market players for Europe foot and ankle allografts market are listed below:
Zimmer Biomet,
Johnson & Johnson Services, Inc.,
Integra Lifesciences
CONMED Corporation.
Stryker,
Bioventus,
AlloSource,
Smith Nephew,
Arthrex, Inc.,
Organogenesis Inc.,
PARAGON 28, INC,
TABLE OF CONTENTS
1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW OF EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET 32
1.4 LIMITATIONS 34
1.5 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 END USER LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTERS FIVE FORCES 52
5 INDUSTRIAL INSIGHTS: 53
5.1 CONCLUSION: 53
6 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 54
6.1 U.S. 55
6.2 CANADA 56
6.3 EUROPE 56
7 MARKET OVERVIEW 58
7.1 DRIVERS 60
7.1.1 GROWING GERIATRIC POPULATION 60
7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 60
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 61
7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 62
7.2 RESTRAINTS 63
7.2.1 STRINGENT REGULATORY 63
7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 63
7.3 OPPORTUNITIES 64
7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 64
7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 65
7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 66
7.4 CHALLENGES 67
7.4.1 COVID-19 IMPACT ON EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET 67
7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 68
7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 69
8 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 70
8.1 OVERVIEW 71
8.2 ALLOGRAFT WEDGES 74
8.3 ALLOGRAFT TENDONS 74
8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 75
8.5 CARTILAGE ALLOGRAFT MATRIX 76
8.6 SKIN ALLOGRAFTS 77
8.7 AMNIOTIC MEMBRANES 78
9 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 79
9.1 OVERVIEW 80
9.2 ORTHOPEDIC RECONSTRUCTION 83
9.2.1 NON-UNIONS FRACTURES 84
9.2.2 ARTHRODESIS PROCEDURES 84
9.2.3 OSTEOTOMY PROCEDURES 84
9.3 CARTILAGE RESTORATION 84
9.3.1 TALAR DOME REPAIR 85
9.3.2 TIBIAL PLAFOND REPAIR 85
9.3.3 METATARSAL REPAIR 85
9.3.4 TALONAVICULAR JOINT REPAIR 85
9.3.5 SUBTALAR JOINT REPAIR 85
9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 85
9.4.1 TENDON AUGMENTATION 86
9.4.2 LIGAMENT REPAIR 86
9.4.3 FAT PAD REPLACEMENT 86
9.4.4 PLANTAR PLATE REPAIR 87
9.5 WOUND CARE 87
9.5.1 ANKLE ULCER TREATMENT 88
9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 88
10 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 89
10.1 OVERVIEW 90
10.2 MIDFOOT PROCEDURES 93
10.2.1 CUBOID FRACTURE 94
10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 94
10.2.3 MEDIAL COLUMN ARTHRODESIS 94
10.2.4 LISFRANC 94
10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 94
10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 94
10.2.7 NAVICULAR FRACTURE 94
10.2.8 OTHER MIDFOOT PROCEDURES 94
10.3 HIND-FOOT PROCEDURES 94
10.3.1 CALCANEAL FRACTURE 95
10.3.2 LATERAL COLUMN LENGTHENING 95
10.3.3 TALONAVICULAR JOINT ARTHRODESIS 96
10.3.4 TRIPLE ARTHRODESIS 96
10.3.5 OTHER HINDFOOT PROCEDURES 96
11 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 97
11.1 OVERVIEW 98
11.2 HOSPITALS 101
11.3 ORTHOPEDIC CLINICS 101
11.4 AMBULATORY SURGICAL CENTERS 102
11.5 ACADEMIC AND RESEARCH INSTITUTES 103
11.6 OTHER END USERS 104
12 EUROPE FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 105
12.1 EUROPE 106
12.1.1 U.K. 115
12.1.2 GERMANY 118
12.1.3 FRANCE 121
12.1.4 ITALY 124
12.1.5 SPAIN 127
12.1.6 RUSSIA 130
12.1.7 SWITZERLAND 133
12.1.8 NETHERLANDS 136
12.1.9 BELGIUM 139
12.1.10 TURKEY 142
12.1.11 REST OF EUROPE 145
13 EUROPE FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 146
13.1 COMPANY SHARE ANALYSIS: EUROPE 146
14 SWOT ANALYSIS 147
15 COMPANY PROFILE 148
15.1 LIFENET HEALTH 148
15.1.1 COMPANY SNAPSHOT 148
15.1.2 COMPANY SHARE ANALYSIS 148
15.1.3 PRODUCT PORTFOLIO 149
15.1.4 RECENT DEVELOPMENTS 150
15.1.4.1 CONFERENCE 150
15.1.4.2 PRODUCT LAUNCH 151
15.2 ZIMMER BIOMET 152
15.2.1 COMPANY SNAPSHOT 152
15.2.2 REVENUE ANALYSIS 152
15.2.3 COMPANY SHARE ANALYSIS 153
15.2.4 PRODUCT PORTFOLIO 153
15.2.5 RECENT DEVELOPMENT 153
15.2.5.1 PARTNERSHIP 153
15.3 JOHNSON & JOHNSON SERVICES, INC. 154
15.3.1 COMPANY SNAPSHOT 154
15.3.2 REVENUE ANALYSIS 154
15.3.3 COMPANY SHARE ANALYSIS 155
15.3.4 PRODUCT PORTFOLIO 155
15.3.5 RECENT DEVELOPMENTS 155
15.3.5.1 EVENT 155
15.3.5.2 PRODUCT LAUNCH 155
15.4 INTEGRA LIFESCIENCES 156
15.4.1 COMPANY SNAPSHOT 156
15.4.2 REVENUE ANALYSIS 156
15.4.3 COMPANY SHARE ANALYSIS 157
15.4.4 PRODUCT PORTFOLIO 157
15.4.5 RECENT DEVELOPMENTS 157
15.4.5.1 POSITIVE CLINICAL OUTCOME 157
15.4.5.2 AGREEMENT 157
15.4.5.3 ACQUISITION 158
15.5 CONMED CORPORATION (2022) 159
15.5.1 COMPANY SNAPSHOT 159
15.5.2 REVENUE ANALYSIS 159
15.5.3 COMPANY SHARE ANALYSIS 160
15.5.4 PRODUCT PORTFOLIO 160
15.5.5 RECENT DEVELOPMENT 161
15.5.5.1 ACQUISITION 161
15.6 ALLOSOURCE 162
15.6.1 COMPANY SNAPSHOT 162
15.6.2 PRODUCT PORTFOLIO 162
15.6.3 RECENT DEVELOPMENT 163
15.6.3.1 PRODUCT LAUNCH 163
15.7 ALON SOURCE GROUP 164
15.7.1 COMPANY SNAPSHOT 164
15.7.2 PRODUCT PORTFOLIO 164
15.7.3 RECENT DEVELOPMENT 164
15.8 AMNIOX MEDICAL INC. 165
15.8.1 COMPANY SNAPSHOT 165
15.8.2 PRODUCT PORTFOLIO 165
15.8.3 RECENT DEVELOPMENT 165
15.8.3.1 PARTNERSHIP 165
15.9 ARTHREX 166
15.9.1 COMPANY SNAPSHOT 166
15.9.2 PRODUCT PORTFOLIO 166
15.9.3 RECENT DEVELOPMENT 166
15.9.3.1 PRODUCT LAUNCH 166
15.10 BIOVENTUS 167
15.10.1 COMPANY SNAPSHOT 167
15.10.2 REVENUE ANALYSIS 167
15.10.3 PRODUCT PORTFOLIO 168
15.10.4 RECENT DEVELOPMENT 168
15.10.4.1 CO-DEVELOPMENT 168
15.11 BONE BANK ALLOGRAFTS 169
15.11.1 COMPANY SNAPSHOT 169
15.11.2 PRODUCT PORTFOLIO 169
15.11.3 RECENT DEVELOPMENTS 169
15.11.3.1 PARTNERSHIP 169
15.12 GLOBUS MEDICAL 170
15.12.1 COMPANY SNAPSHOT 170
15.12.2 REVENUE ANALYSIS 170
15.12.3 PRODUCT PORTFOLIO 171
15.12.4 RECENT DEVELOPMENTS 171
15.12.4.1 M&A 171
15.13 INSTITUT STRAUMANN 172
15.13.1 COMPANY SNAPSHOT 172
15.13.2 REVENUE ANALYSIS 172
15.13.3 PRODUCT PORTFOLIO 173
15.13.4 RECENT DEVELOPMENT 173
15.14 JRF ORTHO 174
15.14.1 COMPANY SNAPSHOT 174
15.14.2 PRODUCT PORTFOLIO 174
15.14.3 RECENT DEVELOPMENT 175
15.14.3.1 PARTNERSHIP 175
15.15 NVISION BIOMEDICAL TECHNOLOGIES. 176
15.15.1 COMPANY SNAPSHOT 176
15.15.2 PRODUCT PORTFOLIO 176
15.15.3 RECENT DEVELOPMENT 176
15.15.3.1 ACQUISITION 176
15.16 PARAGON28, INC. 177
15.16.1 COMPANY SNAPSHOT 177
15.16.2 REVENUE ANALYSIS 177
15.16.3 PRODUCT PORTFOLIO 178
15.16.4 RECENT DEVELOPMENT 178
15.16.4.1 ACQUISITION 178
15.17 ORGANOGENESIS INC 179
15.17.1 COMPANY SNAPSHOT 179
15.17.2 REVENUE ANALYSIS 179
15.17.3 PRODUCT PORTFOLIO 180
15.17.4 RECENT DEVELOPMENTS 180
15.17.4.1 CONFERENCE 180
15.17.4.2 ACQUISITION 180
15.18 SMITH + NEPHEW 181
15.18.1 COMPANY SNAPSHOT 181
15.18.2 REVENUE ANALYSIS 181
15.18.3 PRODUCT PORTFOLIO 182
15.18.4 RECENT DEVELOPMENTS 182
15.18.4.1 EVENT 182
15.18.4.2 ACQUISITION 182
15.19 STRYKER 183
15.19.1 COMPANY SNAPSHOT 183
15.19.2 REVENUE ANALYSIS 183
15.19.3 PRODUCT PORTFOLIO 184
15.19.4 RECENT DEVELOPMENT 184
16 QUESTIONNAIRE 185
17 RELATED REPORTS 188
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
